Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Life Sciences & Biomedicine (4)
- Science & Technology (4)
- Oncology (3)
- ACUTE LYMPHOBLASTIC-LEUKEMIA (1)
- ANTI-TARGET CELL (1)
-
- ANTITUMOR-ACTIVITY (1)
- Alveolar soft part sarcoma (1)
- BISPECIFIC ANTIBODIES (1)
- Biochemistry & Molecular Biology (1)
- Bispecific antibody (1)
- CANCER-IMMUNOTHERAPY (1)
- CATUMAXOMAB (1)
- CHEMOTHERAPY (1)
- CHRONIC LYMPHOCYTIC-LEUKEMIA (1)
- CLINICAL IMPACT (1)
- CLINICAL-TRIALS (1)
- CLL8 TRIAL (1)
- Cancer (1)
- Cell Biology (1)
- Chemotherapy (1)
- Curcumin (1)
- DECREASES (1)
- DOUBLE-BLIND (1)
- Dermatitis (1)
- EFFICACY (1)
- FLUDARABINE PLUS CYCLOPHOSPHAMIDE (1)
- GAMMA-IRRADIATION (1)
- GROWTH-FACTOR RECEPTOR (1)
- Health Care Sciences & Services (1)
- Hematology (1)
Articles 1 - 14 of 14
Full-Text Articles in Medicine and Health Sciences
Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report And Review Of The Literature, F. Safa, M. Pant, C. Weerasinghe, R. Felix, T. Terjanian
Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report And Review Of The Literature, F. Safa, M. Pant, C. Weerasinghe, R. Felix, T. Terjanian
Journal Articles
© 2018 Multimed Inc. Merkel cell carcinoma (MCC) is an uncommon malignancy of the skin arising from cells located in the deeper layers of the epidermis called Merkel cells. This malignancy rarely presents as a metastatic disease, and the field is therefore deficient in regards to management. We report the case of a 49-year-old woman who presented with a presumptive diagnosis of osteomyelitis of the left fifth digit that was resistant to treatment with antibiotics; she underwent debridement of the digit that revealed MCC and was later to have metastatic disease to her lungs, liver, and musculoskeletal system. The management …
Mutation Patterns Identify Adult Patients With De Novo Acute Myeloid Leukemia Aged 60 Years Or Older Who Respond Favorably To Standard Chemotherapy: An Analysis Of Alliance Studies, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, J. S. Blachly, C. J. Walker, D. Nicolet, S. Orwick, S. E. Maharry, J. E. Kolitz, C. D. Bloomfield, +6 Additional Authors
Mutation Patterns Identify Adult Patients With De Novo Acute Myeloid Leukemia Aged 60 Years Or Older Who Respond Favorably To Standard Chemotherapy: An Analysis Of Alliance Studies, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, J. S. Blachly, C. J. Walker, D. Nicolet, S. Orwick, S. E. Maharry, J. E. Kolitz, C. D. Bloomfield, +6 Additional Authors
Journal Articles
© 2018 Macmillan Publishers Limited, part of Springer Nature. Thus far, only 5-15% of AML patients aged ≥60 years are cured with chemotherapy. Identification of patients who are less (more) likely to respond to standard chemotherapy might enable early risk stratification toward alternative treatment regimens. We used a next-generation sequencing panel of 80 cancer- and/or leukemia-associated genes to profile molecularly 423 older patients with de novo AML. Using variables identified in multivariable models and co-occurring mutations in NPM1-mutated AML, we classified the patients into good-, intermediate-, and poor-risk groups for complete remission (CR) attainment, disease-free (DFS), and overall survival (OS). …
Oral Curcumin For Radiation Dermatitis: A Urcc Ncorp Study Of 686 Breast Cancer Patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, +2 Additional Authors
Oral Curcumin For Radiation Dermatitis: A Urcc Ncorp Study Of 686 Breast Cancer Patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, +2 Additional Authors
Journal Articles
No abstract provided.
Hybrid Capture–Based Genomic Profiling Of Circulating Tumor Dna From Patients With Advanced Cancers Of The Gastrointestinal Tract Or Anus, A. B. Schrock, D. Pavlick, S. J. Klempner, J. H. Chung, B. Forcier, A. Welsh, L. Young, B. Leyland-Jones, C. Devoe, V. A. Miller, +9 Additional Authors
Hybrid Capture–Based Genomic Profiling Of Circulating Tumor Dna From Patients With Advanced Cancers Of The Gastrointestinal Tract Or Anus, A. B. Schrock, D. Pavlick, S. J. Klempner, J. H. Chung, B. Forcier, A. Welsh, L. Young, B. Leyland-Jones, C. Devoe, V. A. Miller, +9 Additional Authors
Journal Articles
© 2018 American Association for Cancer Research. Purpose: Genomic profiling of tumor biopsies from advanced gastrointestinal and anal cancers is increasingly used to inform treatment. In some cases, tissue biopsy can be prohibitive, and we sought to investigate whether analysis of blood-derived circulating tumor DNA (ctDNA) may provide a minimally invasive alternative. Experimental Design: Hybrid capture–based genomic profiling of 62 genes was performed on blood-based ctDNA from 417 patients with gastrointestinal carcinomas to assess the presence of genomic alterations (GA) and compare with matched tissue samples. Results: Evidence of ctDNA was detected in 344 of 417 samples (82%), and of …
Nf1 Mutations Are Recurrent In Adult Acute Myeloid Leukemia And Confer Poor Outcome, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, A. Mims, C. J. Walker, J. S. Blachly, D. Nicolet, S. Orwick, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors
Nf1 Mutations Are Recurrent In Adult Acute Myeloid Leukemia And Confer Poor Outcome, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, A. Mims, C. J. Walker, J. S. Blachly, D. Nicolet, S. Orwick, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors
Journal Articles
© 2018 Macmillan Publishers Limited, part of Springer Nature Targeted mutation assessment of 81 genes in 1021 adults with de novo acute myeloid leukemia (AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 52 (5.1%) patients, including 36 (5.2%) younger and 16 (4.8%) older patients, which suggests NF1 belongs to the 20 most frequently mutated genes in adult AML. NF1 mutations were found throughout the gene, and comprised missense, frameshift, and nonsense mutations. One mutation hotspot, at amino acid threonine 676 (Thr676), was found in 27% of AML patients with NF1 mutations. NF1-mutated patients belonged more often to …
Renal Involvement In Chronic Lymphocytic Leukemia., R. Wanchoo, C. Bernabe Ramirez, J. Barrientos, K. D. Jhaveri
Renal Involvement In Chronic Lymphocytic Leukemia., R. Wanchoo, C. Bernabe Ramirez, J. Barrientos, K. D. Jhaveri
Journal Articles
Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe. Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment. Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the monoclonal antibody obinutuzumab are important nephrotoxicities associated with …
Chylothorax In Patients With Chronic Lymphocytic Leukemia: A Case Series., D. Sammartino, S. Khanijo, S. Koenig, J. F. Katsetos, A. Tufano, K. R. Rai, J. C. Barrientos
Chylothorax In Patients With Chronic Lymphocytic Leukemia: A Case Series., D. Sammartino, S. Khanijo, S. Koenig, J. F. Katsetos, A. Tufano, K. R. Rai, J. C. Barrientos
Journal Articles
Chylothorax, which is defined as the presence of chyle in the pleural space, is often caused by malignancy. However, chylothorax as a result of underlying CLL is exceedingly rare in the literature. Chyle contains fat soluble vitamins and lymphocytes, meaning that its collection into the pleural space may further exacerbate the immunosupressed state of an individual with CLL. Here, we report three cases of patients with CLL who developed chylothorax, and their management. Chylothorax, although rare with CLL, should be considered in the differential diagnosis when patients with CLL present with pleural effusions, especially if recurrent. Discovery of a chylothorax …
Bi-Specific And Tri-Specific Antibodies- The Next Big Thing In Solid Tumor Therapeutics, K. Runcie, D. R. Budman, V. John, N. Seetharamu
Bi-Specific And Tri-Specific Antibodies- The Next Big Thing In Solid Tumor Therapeutics, K. Runcie, D. R. Budman, V. John, N. Seetharamu
Journal Articles
No abstract provided.
Extended Follow-Up And Impact Of High-Risk Prognostic Factors From The Phase 3 Resonate Study In Patients With Previously Treated Cll/Sll, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, +20 Additional Authors
Extended Follow-Up And Impact Of High-Risk Prognostic Factors From The Phase 3 Resonate Study In Patients With Previously Treated Cll/Sll, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, +20 Additional Authors
Journal Articles
No abstract provided.
Cpx-351 (Cytarabine And Daunorubicin) Liposome For Injection Versus Conventional Cytarabine Plus Daunorubicin In Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, J. E. Lancet, G. L. Uy, J. E. Cortes, L. F. Newell, T. L. Lin, E. K. Ritchie, R. K. Stuart, S. A. Strickland, J. E. Kolitz, B. C. Medeiros, +11 Additional Authors
Cpx-351 (Cytarabine And Daunorubicin) Liposome For Injection Versus Conventional Cytarabine Plus Daunorubicin In Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, J. E. Lancet, G. L. Uy, J. E. Cortes, L. F. Newell, T. L. Lin, E. K. Ritchie, R. K. Stuart, S. A. Strickland, J. E. Kolitz, B. C. Medeiros, +11 Additional Authors
Journal Articles
© 2018 by American Society of Clinical Oncology. Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of …
Genome-Wide Association Study Identifies An Acute Myeloid Leukemia Susceptibility Locus Near Bicra, C. J. Walker, C. C. Oakes, L. K. Genutis, B. Giacopelli, S. Liyanarachchi, D. Nicolet, A. K. Eisfeld, M. Scholz, J. E. Kolitz, C. D. Bloomfield, +12 Additional Authors
Genome-Wide Association Study Identifies An Acute Myeloid Leukemia Susceptibility Locus Near Bicra, C. J. Walker, C. C. Oakes, L. K. Genutis, B. Giacopelli, S. Liyanarachchi, D. Nicolet, A. K. Eisfeld, M. Scholz, J. E. Kolitz, C. D. Bloomfield, +12 Additional Authors
Journal Articles
No abstract provided.
Activity Of Pazopanib And Trabectedin In Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, +13 Additional Authors
Activity Of Pazopanib And Trabectedin In Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, +13 Additional Authors
Journal Articles
No abstract provided.
Synchronous Presence Of Egfr, Alk Driver Mutations Along With Pd L1 Overexpression In A Resected Early Stage Non-Small Cell Lung Cancer: A Case Report And Review Of Literature., N. Thumallapally, S. Parylo, A. Vennepureddy, U. Ibrahim, A. Sokoloff
Synchronous Presence Of Egfr, Alk Driver Mutations Along With Pd L1 Overexpression In A Resected Early Stage Non-Small Cell Lung Cancer: A Case Report And Review Of Literature., N. Thumallapally, S. Parylo, A. Vennepureddy, U. Ibrahim, A. Sokoloff
Journal Articles
Treatment of lung cancer has been revolutionized with development of drugs that target key driver mutations and immune checkpoints. Until recently, it was believed that these driver mutations are mutually exclusive. However, few reports have emerged citing the presence of both mutations either synchronously or metachronously. We describe a case report of lung adenocarcinoma harboring two driver mutations in the same tumor cells as well as exhibiting high PDL1 expression. We further discuss the possible association of these driver mutations with PDL1 expression.
Discovery And Functional Implications Of A Mir-29b-1/Mir-29a Cluster Polymorphism In Acute Myeloid Leukemia, A. Ngankeu, P. Ranganathan, V. Havelange, D. Nicolet, S. Volinia, B. L. Powell, J. E. Kolitz, G. L. Uy, R. M. Stone, R. Garzon, +4 Additional Authors
Discovery And Functional Implications Of A Mir-29b-1/Mir-29a Cluster Polymorphism In Acute Myeloid Leukemia, A. Ngankeu, P. Ranganathan, V. Havelange, D. Nicolet, S. Volinia, B. L. Powell, J. E. Kolitz, G. L. Uy, R. M. Stone, R. Garzon, +4 Additional Authors
Journal Articles
© Ngankeu et al. We previously reported that microRNA (miR)-29b is down-regulated and has a tumor suppressor role in acute myeloid leukemia (AML). However, little is known about the mechanisms responsible for miR-29b expression downregulation in AML. In this work we screened for mutations that could affect miR-29b expression. Using Sanger sequencing, we identified a germline thymidine (T) base deletion within the miR-29b-1/miR-29a cluster precursor in 16% of AML patients. Remarkably we found a significant enrichment for the presence of the miR-29 polymorphism in core binding factor (CBF) newly diagnosed AML patients (n = 61/303; 20%) with respect to age, …